Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Archives of Internal Medicine

• Publication date

  2006-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHINTE.166.7.737PMID 16606809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease

  2012cited by this paper
• Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

  2005cited by this paper
• Mitochondrial Dysfunction and Type 2 Diabetes

  2005cited by this paper
• Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

  2005cited by this paper
• Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

  2005cited by this paper
• Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary

  2005cited by this paper
• The metabolic syndrome: time for a critical appraisal

  2005cited by this paper
• Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes.

  2005cited by this paper
• Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp

  2005cited by this paper
• Mitochondrial dysfunction and type 2 diabetes

  2005cited by this paper
• Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?

  2004cited by this paper
• Correlation between cardiovascular disease and diabetes mellitus: current concepts.

  2004cited by this paper
• Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease

  2004cited by this paper
• The glucose-fatty acid cycle: a physiological perspective.

  2003cited by this paper
• Bezafibrate improves hypertension and insulin sensitivity in humans.

  2003cited by this paper
• Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome

  2003cited by this paper
• Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.

  2002cited by this paper
• Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia

  2002cited by this paper
• Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.

  2002cited by this paper
• The role of fibric acids in atherosclerosis

  2001influential reference
• Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.

  2001cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Effects of Antihypertensive Therapy on Glucose and Insulin Metabolism and on Left Ventricular Mass: A Randomized, Double-Blind, Controlled Study of 21 Obese Hypertensives

  2000cited by this paper
• Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*

  2000influential reference
• Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X

  2000cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• The Homeostasis Model in the San Antonio Heart Study

  1997cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.

  1995cited by this paper
• Role of insulin resistance in human disease (syndrome X): an expanded definition.

  1993cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper

• Exploring the Association of Lipid-Lowering Drugs with Diabetes: A Comprehensive Review

  2024cites this paper
• Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility

  2022cites this paper
• Association of TG/HDLC ratio trajectory and risk of type 2 diabetes: A retrospective cohort study in China

  2020cites this paper
• Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review.

  2020cites this paper
• Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial patient-oriented and epidemiological research

  2020cites this paper
• BENEFICIAL EFFECTS OF VARIOUS PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR AGONISTS ON LIPID PROFILES AND OBESITY : A REVIEW

  2020cites this paper
• Lipid-lowering Therapies in Myositis

  2020cites this paper
• Contribution and interaction of the low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross‐sectional study

  2018cites this paper
• Hypertriglyceridemia is associated with impaired fasting glucose in normal-weight children

  2018cites this paper
• Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial[S]

  2017cites this paper
• Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice

  2017cites this paper
• The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice

  2017cites this paper
• Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study

  2016cites this paper
• Recherche d'un lien entre les diabétiques de type 2 présentant un syndrome métabolique, et les hypothyroïdies, frustes ou avérées, en Aquitaine

  2015cites this paper
• Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

  2015cites this paper
• Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α[S]

  2015cites this paper
• Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

  2014cites this paper
• Lipoprotein state in families who have history of type 2 diabetes.

  2014cites this paper
• Target network differences between western drugs and Chinese herbal ingredients in treating cardiovascular disease

  2014cites this paper
• Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

  2014cites this paper
• Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

  2014cites this paper
• Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study

  2014cites this paper
• Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies

  2014cites this paper
• Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications

  2014cites this paper
• Peroxisome Proliferator-Activated Receptor-&ggr; Agonists Prevent Tumor Necrosis Factor-&agr;-Mediated Inhibition of FSH-Induced Follicle Development and Estradiol Production in a Preantral Follicle Culture System

  2014cites this paper
• 贝特类调血脂药物的研究进展 The New Idea in the Synthesis of Lipid-Regulator Fibrates

  2014cites this paper
• The New Idea in the Synthesis of Lipid-Regulator Fibrates

  2014cites this paper
• Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

  2014cites this paper
• Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.

  2013cites this paper
• Novel mechanisms for prevention and treatment of type 2 diabetes

  2013cites this paper
• Biochemical Alterations and Endothelial Dysfunction in Hypercholesterolemic Rats: Effects of Bezafibrate

  2013cites this paper
• Effect of bezafibrate on office, home and ambulatory blood pressure in hypertensive patients with dyslipidemia

  2013cites this paper
• Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate

  2013cites this paper
• Mitochondria toxicity of antihyperlipidemic agents bezafibrate and fenofibrate

  2013cites this paper
• Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system

  2013cites this paper
• Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate

  2012cites this paper
• Genetic Predisposition to Dyslipidemia and Type 2 Diabetes Risk in Two Prospective Cohorts

  2012cites this paper
• Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

  2012cites this paper
• Fenofibrate

  2012cites this paper
• Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats

  2012cites this paper
• Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

  2012cites this paper
• Lipids, Atherogenic Dyslipidemia, and Therapy

  2012cites this paper
• Fenofibrate

  2011cites this paper
• "The metabolic syndrome... is dead": These reports are an exaggeration

  2011cites this paper
• Bezafibrate Restores the Inhibition of FSH-Induced Follicular Development and Steroidogenesis by Tumor Necrosis Factor-Alpha Through Peroxisome Proliferator-Activated Receptor-Gamma Pathway in an In Vitro Mouse Preantral Follicle Culture1

  2011cites this paper
• Fenofibrate

  2011cites this paper
• SIMULTANEOUS ANALYSIS OF RPHPLC METHOD DEVELOPMENT AND VALIDATION OF TERBINAFINE AND BEZAFIBRATE DRUGS IN PHARMACEUTICAL DOSAGE FORM

  2011cites this paper
• Fibrates: old drugs with a new role in type 2 diabetes prevention?

  2011cites this paper
• Prediabetes as a therapeutic target.

  2011cites this paper
• Metabolic syndrome, prediabetes and the science of primary prevention.

  2011cites this paper
• Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes

  2011cites this paper
• Mendelian Randomization Studies Do Not Support a Role for Raised Circulating Triglyceride Levels Influencing Type 2 Diabetes, Glucose Levels, or Insulin Resistance

  2011cites this paper
• Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome

  2010influential citation
• "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study

  2010cites this paper
• Diabetic cardiomyopathy: signaling defects and therapeutic approaches

  2010cites this paper
• Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective

  2010cites this paper
• Usefulness of Bezafibrate for Ovulation Induction in Clomiphene Citrate-Resistant Polycystic Ovary Syndrome Patients with Dyslipidemia: A Prospective Pilot Study of Seven Cases

  2010cites this paper
• Causal inference with two-stage logistic regression -accuracy, precision, and application

  2010cites this paper
• Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

  2010cites this paper
• Dyslipidemia: Pathogenesis and Management

  2010cites this paper
• Combination statin–fibrate therapy: safety aspects

  2009cites this paper
• Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer.

  2009cites this paper
• Lipid-Modifying and Antiatherosclerotic Drugs

  2009cites this paper
• Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

  2009cites this paper
• Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia

  2009cites this paper
• Antidiabetic Action of Bezafibrate in a Large Observational Database

  2009cites this paper
• Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease

  2009cites this paper
• Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment

  2009cites this paper
• Interpreting clinical trials of diabetic dyslipidaemia: new insights

  2009cites this paper
• Basic nutritional investigation Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet

  2009cites this paper
• Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes

  2008influential citation
• Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes

  2008cites this paper
• Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

  2008cites this paper
• Fibrate Therapy: An Update

  2008cites this paper
• The Treatment of Dyslipidemia—What's Left in the Pipeline?

  2008cites this paper
• Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor‐β1 in a cultured stellate cell line

  2008cites this paper
• Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).

  2008cites this paper
• Fibrate-associated adverse effects beyond muscle and liver toxicity.

  2008cites this paper
• Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease.

  2007cites this paper
• Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.

  2007cites this paper
• Fibrates: What Have We Learned in the Past 40 Years?

  2007cites this paper
• Therapy and clinical trials.

  2007cites this paper
• Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.

  2007cites this paper
• Management of Gout in Older Adults

  2007cites this paper
• Bibliography. Current world literature. Diabetes and the endocrine pancreas II.

  2007cites this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial

  2007cites this paper
• Review Article Metabolic syndrome and cardiovascular disease

  2007cites this paper
• Metabolic syndrome and cardiovascular disease

  2007cites this paper
• Comment on: Weickert MO, Pfeiffer AFH (2006) Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49:1732–1741

  2007cites this paper
• The role of fibrates in a statin world.

  2006cites this paper
• Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials

  2006cites this paper
• Reply to comment on: Weickert MO, Pfeiffer AFH (2006) Signalling mechanisms linking hepatic glucose and lipid metabolism. Diabetologia 49:1732–1741

  2006cites this paper
• Le syndrome métabolique

  2006cites this paper
• PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

  2006cites this paper
• PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.

  2006cites this paper
• PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

  2006cites this paper
• Cardio Vascular Diabetology Open Access Commentary

  year unknowncites this paper